FDA Perspective of Improving Quality of Biopharmaceuticals

• Summary of the state of QbD and continuation of OBP’s QbD Pilot Program. • Leverage ‘generic’ examples, such as the A-Mab case study to characterize QbD challenges and opportunities to improve biopharmaceutical quality.